She is also host of the rePROs "Fight Back" podcast.
|
|
Repros applied for U.S. marketing approval for Androxal in February 2015, based on data from four studies, two of which compared the drug to a leading FDA-approved treatment.
|
|
Repros said on Tuesday its uterine fibroids drug Proellex stopped severe menstrual bleeding in 52 percent of women enrolled in the trial, pushing the company's shares up 175 percent the next day.
|
|
Repros is conducting an additional study in response to the FDA's request for more data on Androxal, a drug that aims to treat secondary hypogonadism, a condition that leads to low testosterone levels in men, in combination with diet and exercise.
|
|
None have been approved by the Food and Drug Administration as of mid-2010. Androxal consists of an isomer of Clomifene, which is already being used as a generic treatment for male hypogonadism. In December 2017, Allergan announced it was buying Repros Therapeutics. Repros is now operating as a subsidiary of Allergan.
|
|
Steven Henry Madoff, Looking for Thornton Willis: A Treatise, Arts Magazine, Vol. 57, no. 7, March 1983, pp. 116-118, repros.
|
|
3, November 1979, p. 116 During this time he co- founded “Review: Artists on Art” RE-VIEW: Artists on Art Magazine, Vol. II and III, no. 1, June 1979 , repros. pp.
|
|
Repros Therapeutics Inc. (), was a US-based development stage biopharmaceutical company headquartered in The Woodlands, Texas. Founded in 1987 as Zonagen, it is focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski was the CEO of this company.
|
|
Asoprisnil was developed by Germany-based Schering AG to treat endometriosis. Development was discontinued because the drug was causing thickening of the endometrium. Repros claimed that its time on the drug/off the drug approach will make a big difference in safety versus asoprisnil. Currently, products under clinical trial are Proellex and Androxal.
|
|
In 2017, the company acquired LifeCell, a specialist in regenerative medicine, for $2.9 billion and Zeltique Aesthetics, maker of CoolSculpting, for $2.4 billion. On June 7, the company announced the acquisition of Keller Medical, a company that manufactures devices for use during breast augmentation surgery. On December 12, the company announced the acquisition of Repros Therapeutics, a developer of drugs for reproductive system diseases. In September 2018, Allergan acquired the aesthetic company, Bonti, for $195 million.
|
|
In May 2006 Gedeon Richter signed a development and supply agreement with the US- based company Repros Therapeutics to produce Proellex. In July 2007 Gedeon Richter signed a contract with Barr Pharma for the production of Novartis Lamisil. Barr paid Gedeon Richter a royalty for distributing the product in the U.S. From July 2008 - April 2012, the company constructed a new manufacturing facility ($110 million) in Debrecen. In October 2010, Gedeon Richter acquired 100% of a private Swiss biopharmaceutical company, PregLem, for CHF 445 million (€337 million).
|
|
Before joining Monsanto, Podolski held positions in manufacturing, engineering, quality control and development of fine chemicals, antibiotics, pharmaceuticals and hospital products with Abbott Laboratories, Dearborn Chemical Company and Baxter Pharmaceuticals. Joseph S. Podolski, the man who led Zonagen through two decades, decided it was time for a name change. In 2006, Zonagen changed its name to Repros Therapeutics, started to develop other pharmaceutical products for the reproductive system, and began work on its fourth lead drug, Proellex. Proellex is a very similar drug to asoprisnil.
|
|
In 1987, a pharmaceutical company called Zonagen (later renamed Repros Therapeutics) was started with the goal of developing zona pellucida vaccines as an alternative to the surgical sterilization of companion animals and eventually as a contraceptive for human use. The products would be based on research being done at the Baylor College of Medicine by Bonnie S. Dunbar that was funded by Zonagen. However, the relationship between Zonagen and Bonnie Dunbar ended acrimoniously in 1993. Despite claims later that year that development of a contraceptive vaccine was imminent and an agreement with Schering AG for funding for joint development of a contraceptive vaccine for human use, no vaccine was made commercially available and the agreement with Schering was terminated after primate studies were disappointing.
|
|